Clinical Trial: Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational
Official Title: Effect of the Plasma EBV DNA Concentration Change During Chemoradiotherapy on Tumor Control and Patient Survival in Advanced Nasopharyngeal Carcinoma
Brief Summary: Epstein-Barr virus (EBV) has been proven to process a strong association in patient of nasopharyngeal carcinoma (NPC). Monitoring plasma EBV DNA in NPC patients can provide reliable informations in early detecting tumor recurrence or risk grouping.
Detailed Summary: EBV DNA has strongly association in NPC patient' disease status. It can provide informations of disease relapse or risks classification. In this study, we will investigate the impact of plasma EBV DNA concentration change during chemoradiotherapy on initial tumor response and long-term survival in patients with advanced nasopharyngeal carcinoma
Sponsor: Taichung Veterans General Hospital
Current Primary Outcome: Overall survival (OS) [ Time Frame: 2 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Progression free survival (PFS) [ Time Frame: 2 years ]Survival calculation
- Nasopharynx failure-free survival (NPFFS) [ Time Frame: 2 years ]Survival calculation
- Neck failure-free survival (NFFS) [ Time Frame: 2 years ]Survival calculation
- Distant metastasis failure-free survival (DMFFS) [ Time Frame: 2 years ]Survival calculation
- Tumor response [ Time Frame: 2 years ]Tumor response evaluated by image
- EBV DNA concentration [ Time Frame: 2 years ]Plasma EBV DNA by real-time polymerase chain reaction (PCR)
Original Secondary Outcome: Same as current
Information By: Taichung Veterans General Hospital
Dates:
Date Received: March 6, 2017
Date Started: April 1, 2017
Date Completion: January 16, 2019
Last Updated: March 16, 2017
Last Verified: March 2017